Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.
The assay will include a multiplexed panel of established and emerging biomarkers and will be the first RNA-based assay on the Idylla platform using FFPE samples.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The funding is being provided under the NYGC's Polyethnic-1000 initiative, which was launched in 2018 to study cancer care inequities in underserved populations.
The agency approved the test for use across solid tumors and with multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.
The San Diego-based firm anticipates launching an LDT for early-stage lung cancer out of a CLIA-certified, CAP-accredited lab within the next two years.
